Such an important reminder … ...to investors and for newbies ...
https://stockhouse.com/news/press-releases/2023/04/18/spectral-medical-announces-positive-results-of-euphas-2-clinical-trial
Essentially they reported very positive results from the Euphas 2 study ( using PMX and Spectral's EAA) They reported a 28-day mortality of just 36% with the treated patients ( total of 50) versus a predicted 75% mortality utilizing the widely accepted SAPS II mortality estimation tool. This represents a more than 50% estimated relative mortality reduction with the use of PMX ! The patient population of the Euphas 2 study aligns with the patient population of the Tigris Trial.
24 to go to complete Tigris lately averaging 9 new patients per month across 23 sites in the US.
Do you think Baxter ( Vantive) and any tire kicking PE Firms are not closely monitoring the progress on a potential annual $2B+ USD FDA approved, pioneering treatment for Sepsis?
MM